Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics

International Journal of Antimicrobial Agents

Volumn 44, Issue 6, 2014, Pages 493-499

  Cochrane, Stephen A ^a   Vederas, John C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibiotic; Gram negative bacteria; Lipopeptide; Rifampicin; Tridecaptin; Vancomycin

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; DAPTOMYCIN; GALLIDERMIN; LIPOPEPTIDE; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; UNACYLATED TRIDECAPTIN A1; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; PEPTIDE; TRIDECAPTINS;

ACINETOBACTER BAUMANNII; AMINO TERMINAL SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; LIPOPHILICITY; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTER MEMBRANE; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; STRUCTURE ACTIVITY RELATION; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER JEJUNI; CELL LINE; CELL SURVIVAL; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; HUMANS; KLEBSIELLA PNEUMONIAE; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDES; RIFAMPIN; VANCOMYCIN;

EID: 84912077873     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.08.008     Document Type: Article

References (30)

1. N.I. Paphitou Antimicrobial resistance: action to combat the rising microbial challenges Int J Antimicrob Agents 42 2013 S25 S28
2. M.S. Butler, M.A. Blaskovich, and M.A. Cooper Antibiotics in the clinical pipeline in 2013 J Antibiot (Tokyo) 66 2013 571 591
3. T. Roemer, and C. Boone Systems-level antimicrobial drug and drug synergy discovery Nat Chem Biol 9 2013 222 231
4. L.S. Tzouvelekis, A. Markogiannakis, M. Psichogiou, P.T. Tassios, and G.L. Daikos Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions Clin Microbiol Rev 25 2012 682 707
5. G.C. Lee, and D.S. Burgess Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports Ann Clin Microbiol Antimicrob 11 2012 32
6. L.B. Gasink, P.H. Edelstein, E. Lautenbach, M. Synnestvedt, and N.O. Fishman Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae Infect Control Hosp Epidemiol 30 2009 1180 1185
7. N. Karah, A. Sundsfjord, K. Towner, and O. Samuelsen Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii Drug Resist Updat 15 2012 237 247
8. R. Cantón, M. Akóva, Y. Carmeli, C.G. Giske, Y. Glupczynski, and M. Gniadkowski European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe Clin Microbiol Infect 18 2012 413 431
9. M. Vaara, J. Fox, G. Loidl, O. Siikanen, J. Apajalahti, and F. Hansen Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents Antimicrob Agents Chemother 52 2008 3229 3236
10. C. Vingsbo Lundberg, T. Vaara, N. Frimødt-Moller, and M. Vaara Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice J Antimicrob Chemother 65 2010 981 985
11. M.P. Mingeot-Leclercq, P.M. Tulkens, S. Denamur, T. Vaara, and M. Vaara Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells Peptides 35 2012 248 252
12. M. Vaara, H.S. Sader, P.R. Rhomberg, R.N. Jones, and T. Vaara Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens J Antimicrob Chemother 68 2013 636 639
13. M. Vaara, and T. Vaara The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells Int J Antimicrob Agents 41 2013 292 293
14. G. Pirri, A. Giuliani, S.F. Nicoletto, L. Pizzuto, and A.C. Rinaldi Lipopeptides as anti-infectives: a practical perspective Cent Eur J Biol 4 2009 258 273
15. S.A. Cochrane, and J.C. Vederas Lipopeptides from Bacillus and Paenibacillus spp.: a gold mine of antibiotic candidates Med Res Rev 2014 (Epub ahead of print). doi: 10.1002/med.21321
16. T. Kato, H. Hinoo, and J. Shoji The structure of tridecaptin A (studies on antibiotics from the genus Bacillus. XXIV) J Antibiot (Tokyo) 31 1978 652 661
17. 1, an antagonist of Campylobacter jejuni ChemBioChem 15 2014 243 249
18. 1 J Med Chem 57 2014 1127 1131
19. M. Vaara, and T. Vaara Sensitization of Gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide Nature 303 1983 526 528
20. P. Viljanen, and M. Vaara Susceptibility of Gram-negative bacteria to polymyxin B nonapeptide Antimicrob Agents Chemother 25 1984 701 705
21. M. Vaara, O. Siikanen, J. Apajalahti, J. Fox, N. Frimodt-Møller, and H. He A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane Antimicrob Agents Chemother 54 2010 3341 3346
22. I. Wiegand, K. Hilpert, and R.E. Hancock Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances Nat Protoc 3 2008 163 175
23. S. Thennarasu, D.K. Lee, A. Tan, U. Prasad Kari, and A. Ramamoorthy Antimicrobial activity and membrane selective interactions of a synthetic lipopeptide MSI-843 Biochim Biophys Acta 1711 2005 49 58
24. M. Pate, and J. Blazyk Methods for assessing the structure and function of cationic antimicrobial peptides Methods Mol Med 142 2008 155 173
25. J.C. Stewart Colorimetric determination of phospholipids with ammonium ferrothiocyanate Anal Biochem 104 1980 10 14
26. R.R. Bonelli, T. Schneider, H-G. Sahl, and I. Wiedemann Insights into in vitro activities of lantibiotics from gallidermin and epidermin mode-of-action studies Antimicrob Agents Chemother 50 2006 1449 1457
27. C. Watanakkunakorn Mode of action and in-vitro activity of vancomycin J Antimicrob Chemother 14 1984 7 18
28. P. Capepari, M. Boaretti, M.M. Lleo, and G. Satta Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032) Antimicrob Agents Chemother 34 1990 1220 1226
29. J.N. Hansen Nisin as a model food preservative Crit Rev Food Sci Nutr 34 1994 69 93
30. 1 analogues linked to stable secondary structure in the membrane ChemBioChem 15 2014 1295 1299